Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Basic helix-loop-helix ARNT-like protein 1 (BMAL1) is a core circadian transcription factor, encoded by the ARNTL gene in humans, and is essential for generating and maintaining circadian rhythmicity in both behavior and physiology. BMAL1 forms heterodimers with CLOCK, another bHLH-PAS transcription factor; this complex binds E-box motifs in DNA to drive rhythmic expression of a broad set of clock-controlled genes, including other clock regulators such as PER and CRY family members. BMAL1 influences numerous biological processes, including metabolism, immune cell function (such as pro-inflammatory cytokine production in macrophages), autophagy in neural cells, and bone/cartilage homeostasis. BMAL1 deficiency disrupts circadian oscillations and is associated with diverse disorders, including metabolic syndrome, neurological disease, cancer, immune dysfunction, and altered sleep cycles. Therapeutically, BMAL1 is considered a promising target in chronobiology and metabolic disease, though direct pharmacological targeting remains experimental due to its wide-ranging systemic effects.
Agents modulating clock gene expression may influence BMAL1 by altering its transcriptional activity, post-translational modifications, or dimerization with CLOCK protein. For example: CK1 inhibitors modulate circadian protein stability. REV-ERB agonists/antagonists alter feedback on BMAL1 expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Basic helix-loop-helix ARNT-like protein 1 (BMAL1).